It is generally acknowledged that animal experiments provide the most important and best reliable service of information for assessing the possible carcinogenic activity of chemicals. In the past, experimental procedure has mainly concentrated on the choice of species, improved animal husbandry, the modes of exposure, test conditions and pathological examination. Although experience gained thereby indicated the necessity for further scientific exploitation of bioassay models, the rather rigid stereotyped procedures-proposed for convenience-were generally accepted and adopted. Nevertheless, continuous improvements have been made in the design of carcinogenicity tests in rodents. Current developments in test design tend to be primarily concerned with the predictive significance of carcinogenicity studies. Modern protocols call for optimum facility operation as much as for computerized support of study monitoring and data evaluation. Of particular significance are the automated handling of autopsy and histopathological data and their proper statistical evaluation. By the economical use of modern technology, cost-saving protocols can be designed for the production of the data which are essential for the reliable assessment of risk.
INTRODUCTION
The basic requirements for adequate testing of substances suspected of being carcinogenic to man were formulated more than 20 years ago (CLAYSON, 1962 ). The classical system for the detection of chemical carcinogenesis is the in vivo long-term testing, using laboratory rodents and, putting it in a rather simplified manner, the incidence of observed tumors in the test animals is compared with findings in control animals. When a significant increase in malignancies is observed as a result of treatment, the substance is usually labelled as a carcinogen unless exonerating factors are present. The main conclusions of the animal tests, although of a basically qualitative nature, have suggested * Presented at the Second International Symposium of the Society of Toxicologic Pathologists, Session I: "Protocols Past and Present", hlay 9-11, 1983, Arlington, Virginia. This Symposium section will be continued in Volume 11.
Number 2. 1983. strong correlations between human and experimental data (TOMATIS, 1979; IARC 1982) .
However, the purpose of carcinogenicity testing is also to ascertain whether the longterm exposure of laboratory animals to high doses of a substance causes an excess of tumors in order to determine if, at lower dose levels equivalent to human exposure, a risk of cancer is to be expected. As a consequence, the emphasis on carcinogenicity testing has shifted toward quantitative risk assessment and to the possibility of extrapolation to other species, including man. At least for certain potent carcinogens, the pharmacological principles of quantitative relationship between total dose and tumor yield, and daily dose and latent period have been established by DRUCKREY et al. (1963) . Using diethylnitrosamine for instance, a (linear) relationship between the dose levels (d) administered to groups of rats and the times (t) of carcino-TOXICOLOGIC PATHOLOGY gen administration required to yield the same tumor incidence in all the animals was established and expressed by the equation dt" = const. The power of time amounted to n > 1, it being the tangent of the slope of the regression line.
CARCINOGENICITY TESTING REQUIREMENTS

The Testing Procedures
It is evident that the major prerequisite for obtaining reliable results which can be quantitatively interpreted, demands carefully and adequately designed study protocols. The need for standardization became apparent very soon in order to unify divergent opinions on minimal and optimal testing requirements and to facilitate the comparison of results obtained in different laboratories. In Europe, between 1954 and 1964 several working groups made recommendations for the testing of chemicals suspected of being carcinogenic to man (BERENBLUM, 1969) . In fact, already in 1961, testing procedures similar to those introduced in the USA by the Food and Drug Administration were formulated by the World Health Organisation's FAO/WHO-Expert Committee on Food Additives (WHO, 1961) .
The various authorities found agreement on the main principles and it is interesting to note that at this period in time the FAO/ WHO Committee drew attention to the quality of reported work. They criticized the publication of experimental studies of poor quality as this could lead to an unfounded and non-scientific assumption that a compound could (may be incorrectly) present a carcinogenic risk. Suggestions with regard to the reporting were also issued in Annex 2 of the 1961 FAO/WHO report.
The application and design of animal carcinogenicity tests has not changed .substantially over the last decade, except for the fact that the practical conditions of carcinogenesis studies became largely determined by the necessity to continue the treatment and observation period for all or most of the animals' life span and to maintain adequate numbers of animals for complete pathology and statistical evaluation. This seemingly commonsense requirement has had important consequences. They have been compiled more or less explicitly, in various reports from a variety of official committees (cf. MAGEE, 1970) in national guidelines (ALDER et al., 1981; DHSS, 1982) and in several reports under WHO sponsorship issued in the period [1969] [1970] [1971] [1972] [1973] [1974] [1975] .
The European Point of View
In Europe, recent legislation relating to classification and labelling of new chemicals requires carcinogenicity tests as "additional" information. This may be demanded (a) if there is evidence of genotoxicity in non-bacterial systems of a chemical intended for the sale or distribution where production exceeds a specified limit (6th Amendment of the EEC Council Directive 67/548 of 1979; French Law on the Control of Chemical Products of 1979, and the German Chemical Product Control Act of 1981), (b) if carcinogenicity is suspected on grounds of chemical analogy or biological activity, or (c) if a drug is administered to man for a prolonged period of time (EEC Directive 75/318 of 1975).
These directives and numerous other national provisions relating to medicinal products, foodstuffs, pesticides etc. specify that tests must be conducted according to scientifically recognized methodology but they do not usually propose structured guidelines for testing.
In 1981, the Organisation for Economic Cooperation and Development (OECD) formulated internationally-agreed upon guidelines which are anticipated to be eventually issued as a EEC Directive. The 24 member countries will also incorporate these guidelines in their respective National Regulatory Standards. The aim is to achieve mutual acceptance of data, to reduce duplicative testing and to promote cost-effectiveness (PAGE, 1982) . Of particular relevance to the present discussion are the Guidelines for Health Effects, No. 451 on Carcinogenicity and No. 453 on Combined Chronic Toxicity/Carcinogenicity Studies. Anticipating the official commitments, the laboratories of the European chemical industries are largely adapting the OECD guidelines, in particular the Principles of Good Laboratory Practice (GLP) adopted May 12, 1981, by the OECD Council. There are no differences of practical importance between the OECD guidelines for long-term studies of chemicals and the present EC requirements for pharmaceuticals (Table I) .
STUDY DESIGN
In spite of the apparent unanimity with regard to carcinogenicity testing, three main areas of controversy relating to the study protocol still exist, namely (a) on dose selec- The basic requirements in designing a chronic toxicity/carcinogenicity study are summarized in Table 11 . This is a multidiscipline operation demanding specialists in disciplines such as physiology, biochemistry, pharmacology, pathology, animal husbandry, nutrition, analytic chemistry and statistics.
As the result of conducting our studies according to regulations or guidelines (e.g. GLP) promulgated by regulatory agencies our department has experienced a 4-fold increase in the volume of processed data. Obviously, this can only be put in operation by the use of a suitable data management system.
Data ~a~~/~~g
A computerized data handling system is essential for dealing with the flood of information and is consequently justified for use in the time consuming and expensive animal studies.
Data processing in toxicology involves a multitude of operations which are related to data capture and data processing. In view of the fact that in the course of a long-term (carcinogenicity) study wkll over ~~~,~~~ items of data are collected, the use of electronic data processing is indispensable.
Therefore, in the context of the experimental procedures, data processing and reporting of the results, a complex intricate network of interactions has to be considered. This may involve time-table control, control of completeness, the performance of plausibility tests and of audits. Furthermore, statistical tests and other means of securing the interpretation of the data will have to be added.
It is important to realize that there are different classes of data (Table 111) .
Census data which are generally provided by the protocol (except mortalities); numerical data which can be captured by suitable electronic equipment (balance, automated analyzers) and non-numerical data (e.g. symptoms, findings in pathology). The latter are difficult to capture as they involve human interpretation which is in part subjective.
Furthermore, the amount of non-numerical and census data is difficult to estimate because they are interrelated in a complex fashion: new input requires the recourse to existing data.
GLP requires additional census information for data input: date, time of input, and identification of responsible person. As a consequence of GLP requirements, one set of census data is required for each animal for all data entries.
The Computer Systems
In principle there are two possibilities: (a) the use of desk-top computers with or without subsequent central computer (mainfram,e) processing, or essing system.
(b) to introduce an integrated on-line proc-
Data capture with desk-top computers is still used by a number of animal laboratories to facilitate their data entry sessions, to document the data and to perform some statistical work. However, this sort of system is practical only for numerical data which require limited handling.
As a further step, desk-top computers are connected to a mainframe. In our own facility for instance, HP 9830 desk computers have been used for data capture on magnetic tape cartridges. Some of them serve as remote terminals connected to telephone modems and transmit the data to an IBM 3033 mainframe.
The advantages and disadvantages of this type of system are summarized in Table IV .
In order to improve the shortcomings of the decentralized system and to avoid a logistic "nightmare" of the data carriers we have recently implemented an integrated on-line processing system. Such a system should be capable of combining and monitoring all activities at all levels, to guarantee compliance with Good Laboratory Practice and to process numerical as well as non-numerical data.
The requirements and concept of the online system are given in Table V. The concept involves a TANDEM non-stop system comprising three processors, each acting separately, which are connected via two high performance buses (Dynabus, 10 Mbyte/ sc) acting redundantly. Programmable checkpoints guarantee the mutual surveillance and back-up; the central processing units (CPU's) exchange "I am alive" messages; if any CPU fails the survivor will take over. Each terminal has access to two processors and all ports are at least double. Every executing program 
Concept
-Three processor TANDEM non-stop system -Expansible up to 16 processors without software --Back-up process to every running process -Industrial terminals with interfacing options for equipment in the animal rooms/laboratories -0ffice-type terminals for monitoring, text processing and reporting change ("process") has a mirrored counterpart on another processor (for back-up purposes) which is always "up-to-date" but otherwise quiescent. Consequently there are always at least two independent ways to perform any given transaction.
The Approach to Non-numerical Data
The most important aspect of non-numerical data capture involves the computer assisted support for pathology data at autopsy and during the histopathological examination.
The simple solution of storage as free text ("electronic note book") renders structured retrieval and automated evaluation including statistics of the data impossible.
A satisfactory system necessitates the use of dictionaries (glossaries) limiting the vocabulary to the necessary minimum which is still consistent with precise scientific evaluation. Due to the subjective nature of the interpretation of histopathological findings, standardisation of nomenclature is indispensable. In our experience, consensus of opinion can always be reached between pragmatic pathologists and synonyms and ambiguities can be avoided. Scientific accuracy requires the adequate description of any term and its proper documentation.
In our department, D.C. Naylor (1981) has perfected a comprehensive system (first devised and still in use at the Pfizer Research Centre, Amboise, France) by introducing SNOMED (Systematized Nomenclature of Medicine). The major advantage of this system of which we use the Topographical (T) and Morphological (M) Fields, lies in its well structured terminology and vast reserve capacity. The T and M fields are of a strictly hierarchical and orthogonal design (i.e. an entry in one field is absolutely independent and cannot be expressed by entries in other fields).
Computer-based lexica are used for macroscopy and histopathoIogy, one for T sites and another for M changes; they were defined by extracting those terms from SNOMED that are required and adding others that are not present, using spare code numbers.
A computer-assisted system of this sort has been found to be ideally suited for the reporting and evaluating of pathology data in carcinogenicity studies.
Dose Selection
The selection of an appropriate set of dose levels is of particular concern in devising the protocol. Present guidelines offer no particular help in that they uniformly aim at demonstrating qualitative evidence of carcinogenicity or "non-carcinogenicity". The question whether the high dose should be the "maximum tolerated" (SONTAG et al., 1976; DHSS, 1982) or the "minimal toxic" level (OECD, 1981) is rather academic as high-dose effects are notoriously difficult to foretell. What is important, however, is some sort of prediction of the dose-response relationship at the lower dose level in the event of a tumorigenic effect being observed at high . levels of exposure. The explanation of the dose-response relationship at low doses is essential to quantitatively extrapolate the data and is fundamental to cancer risk assessment (FOOD SAFETY COUNCIL, 1980) . The information required for the selection of the most appropriate doses is usually provided by carefully conducted subchronic studies, preferentially of three months duration. The results will provide some idea of the dose-response curve to be expected. Quantitative extrapolation models may be used for this purpose (MUNRO and KREWSKI, 1981) . With the exception of the one-hit model, other mathematical models such as the logit, Weibull and multi-hit will usually fit the data within the experimentally observable range. In the event that, due to inappropriate progressing of dose levels, effects are seen only at the highest dose level, all the models will simulate nearly a linear dose-response. Since the mathematical models involve more than one parameter, the optimal experimental design will involve at least two non-zero dose levels (the higher level being the maximum tolerated or minimal toxic dose) and a zero or control dose level in order to account for the background response. In practice, however, a four-dose design appears preferable as the high dose group may be lost due to premature mortality or the low dose may provide "zero" response equal to the control. From the various possibilities of design (PORTIER and HOEL, 1982) it may be practical to use linear progression of doses and equal allocation of animals to the groups, a procedure which conforms to most guidelines.
Mode of Termination
In contrast to chronic toxicity testing whose aim is to assess effects on longevity, in a carcinogenicity study the attempt should be made to maximize the chance of observing a tumor-producing effect in a relatively small population of test animals. If the treatment does not shorten the animals' lifespan, the duration of the study should encompass the higher proportion of life expectance which, in rats and mice, it will usually be 24 months, under optimal hygienic conditions. Ideally, the surviving animals may then be killed, as the proper evaluation of the findings will depend on incidence rates corrected for time of exposure and survival.
Statistical Considerations
To determine whether a particular chemical is carcinogenic, the incidence rates of a particular tumor in the treated groups is usually compared with its spontaneous incidence in the controls. However, important differences between the percentage of tumor bearing animals in different groups can arise by chance or because of some systematic or toxic effect on longevity. Consequently, three steps are required to interpret the experimental data (PET0 et al., 1980): (a) Correction for effects of differences in longevity: Age-specific tumor onset rates by comparison of observed with expected number of tumor-bearing animals at death. (b) Calculation of significance level (onetailed P-value for positive trend with respect to dose).
(c) "Context of observation" Visual display comparing dependence of tumor rates on age in different treatment groups (e.g. Kaplan-Meier, maximum likelihood graphs).
CONCLUSION It is considered that present-day protocols for long-term studies, whether derived from US or European guidelines are capable of revealing the end-result of highly complex sets of interactions involved in a given carcinogenic process. Internationally agreedupon guidelines, such as those issued by OECD may guarantee an uniformly high standard and, hopefully, will lead to the mutual recognition of test data among countries (HUNTER and MORRIS, 1982) . Owing to the large amount of skilled manpower, time and money required for carcinogenicity tests, an optimum study design is indispensable for producing reliable results. The optimum design incorporates computerized data handling in order to analyse and represent all information gathered in the course of the study in such a way which makes it suitable for risk asses'sment purposes.
